Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

FOLFIRINOX (FX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have been reported as effective regimens for unresectable advanced pancreatic cancer (APC). FX may be more effective but is also associated with more adverse events (AEs). Therefore, first-line treatment with FX followed by second-line...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med
Autors principals: Mita, Naoki, Iwashita, Takuji, Uemura, Shinya, Yoshida, Kensaku, Iwasa, Yuhei, Ando, Nobuhiro, Iwata, Keisuke, Okuno, Mitsuru, Mukai, Tsuyoshi, Shimizu, Masahito
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616879/
https://ncbi.nlm.nih.gov/pubmed/31146420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8060761
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars